Product Information
TAFLUPROST 0.0015% EYE DROP is a generic product labeled by Sandoz Inc., priced at $2.4535 per EA under NDC 00781618487. Its NADAC has been published 189 times since Feb 22, 2023.
FDA first approved this application on Jan 28, 2022. Its Orange Book therapeutic-equivalence code is AT.
Strength
.0045 mg/.3mL
Manufacturer
Sandoz Inc.NDC
00781618487
Classification
Generic
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
TAFLUPROSTApproval Type
Generic (ANDA)
FDA Application
ANDA209040FDA Approved
1/28/2022
TE Code
AT
On Market Since
12/5/2022
Pharmacological Classes
Price Statistics
The NADAC for TAFLUPROST 0.0015% EYE DROP has been published 189 times since Feb 22, 2023, and over the history we have for it it has declined 42.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.4535 per EA |
|---|---|
| All-time high | $4.7773 (May 10, 2023) |
| All-time low | $2.3815 (Jul 22, 2026) |
| 52-week high | $3.0301 |
| 52-week low | $2.3815 |
| Median price | $3.3924 |
| Average price | $3.4751 |
| Largest weekly change | +36.0% (Jun 19, 2024) |
| Weeks tracked | 189 |
| Tracking since | Feb 22, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Tafluprost market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tafluprost market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Prostaglandin Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TAFLUPROST 0.0015% EYE DROP?
The current National Average Drug Acquisition Cost (NADAC) for TAFLUPROST 0.0015% EYE DROP, manufactured by Sandoz Inc., is $2.4535 per EA (NDC 00781618487), effective Sep 30, 2026.
How has the price of TAFLUPROST 0.0015% EYE DROP changed over time?
Over the history we have for it, the NADAC for TAFLUPROST 0.0015% EYE DROP has declined 42.9%. It has been tracked across 189 weekly CMS publications since Feb 22, 2023.
What are the highest and lowest recorded NADAC prices for TAFLUPROST 0.0015% EYE DROP?
Since Feb 22, 2023, the NADAC for TAFLUPROST 0.0015% EYE DROP has ranged from a low of $2.3815 (Jul 22, 2026) to a high of $4.7773 (May 10, 2023), with a median of $3.3924 per EA.
Are there cheaper alternatives to TAFLUPROST 0.0015% EYE DROP?
No other NADAC-published product currently shares the active ingredient and strength of TAFLUPROST 0.0015% EYE DROP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TAFLUPROST 0.0015% EYE DROP?
TAFLUPROST 0.0015% EYE DROP (NDC 00781618487) is labeled by Sandoz Inc., and CMS classifies it as a generic product.